Accepted clinical evidence suggests superior efficacy of novel antipsychotics in the treatment of cognitive symptoms in schizophrenia. Whether this constitutes a primary drug effect or a secondary effect due to easing extrapyramidal side-effects or improving positive symptoms when converting from a first-to a second-generation neuroleptic is still open to debate. Long-term efficacy as well as differential drug effects on cognitive performance are also poorly documented. We therefore compared cognitive performance of olanzapine vs. clozapine treatment in a controlled, randomized, double-blind trial. Fifty-four patients were assessed following a 2-to 9-day washout and again after 4 and 26 wk of neuroleptic treatment. Patients were rated on the PANSS for psychopathological changes, extrapyramidal side-effects were assessed on the Simpson-Angus Scale, and cognitive performance was assessed with the Stroop, Wisconsin Card Sorting and the Tower of London tests. Schizophrenia symptoms, extrapyramidal sideeffects and cognitive performance improved significantly in the course of either drug treatment. Stroop test performance and Tower of London planning time improved significantly over 26 wk compared to baseline and 4-wk follow-up assessment while Wisconsin Card Sorting and Tower of London execution time improved significantly after 4 wk with no further improvement after 26 wk. Improved executive function was not related to improving positive symptoms and easing extrapyramidal side-effects, thus indicative of a primary treatment effect of either antipsychotic. However, Stroop reaction time improved with olanzapine while clozapine had a stronger effect on improving negative symptoms, thus suggestive of a differential drug effect.
Introduction
Newer so-called 'atypical ' neuroleptics are considered to improve cognitive functioning, including executive functioning, in patients with schizophrenia (Meltzer and McGurk, 1999) . Executive functioning, the ability to plan and monitor one's behaviour, to set goals, anticipate results and use feedback, is a cognitive component strongly associated with important aspects of functional outcome such as social and occupational functioning (Green, 1996 ; Jaeger et al., 1992 ; Meltzer et al., 1996) . Enhancement of executive functioning thus has the potential to improve social, functional and adaptive outcome.
It is still not clear whether the improvement of executive functioning is due to primary effects of the 'atypical ' neuroleptics or due to secondary effects like the easing of extrapyramidal side-effects (EPS) or the improvement of psychopathology following the conversion from a 'typical ' to an 'atypical ' neuroleptic. The main drawbacks of previous studies include small sample sizes, an open-label approach, brief observation periods and the comparison with 'typical ' instead of other 'atypical ' neuroleptic agents (Keefe et al., 1999) . Especially comparisons with 'typical ' neuroleptic agents, like haloperidol, may lead to wrong conclusions, as many cognitive tasks require some kind of motor response that may be secondarily impaired by EPS (Harvey and Keefe, 2001) .
The Tower of London test (ToL ; Shallice, 1982) , the Stroop test (Stroop, 1935) and the Wisconsin Card Sorting test (WCST ; Grant and Berg, 1948) are widely used measures of executive functioning. Performance on all three tests is impaired in schizophrenia (Greve et al., 1998 ; Hepp et al., 1996 ; Morris et al., 1995) . Atypical antipsychotics are reported to enhance test performance in the ToL (Schall et al., 1998) and to a lesser extent in the WCST (Meltzer and McGurk, 1999) , but not in the Stroop test (Liddle and Morris, 1991) . Frith (1992) divided the underlying cognitive functions into stimulus-driven (as measured by the Stroop test) and concept-driven processing (WCST, ToL) and claimed that the latter aspect is predominantly affected in schizophrenia. Cuesta and Peralta (1995) proposed a strong general relationship between cognitive dysfunction and negative and disorganized symptoms, but not with positive symptoms of schizophrenia. However, the influence of neuroleptic medication is an important factor when assessing neuropsychological deficits in schizophrenia. The results of Liddle and Morris (1991) , claiming a relationship of ' frontal ' cognitive tests with negative symptoms and disorganization, could not be replicated by Himelhoch et al. (1996) in an unmedicated sample.
In the short-term course of treatment, through the change from a 'typical ' neuroleptic like haloperidol to an 'atypical ' like olanzapine or clozapine EPS should be eased (Miller et al., 1998) and negative symptoms of the disease should be improved more than would be by a conventional neuroleptic . Changes in executive functioning at this point can either be due to secondary effects of these improvements or primary effects of the neuroleptic substances. Secondary effects would occur relative to changes in psychotic (positive) symptoms or the reduction of side-effects, primary effects would be independent of these changes. Previous studies (cf. Keefe et al., 1999 ; Meltzer and McGurk, 1999) suggest a primary effect of olanzapine and clozapine on executive functioning in the short-term course of treatment.
The inconsistency of previous study results for the ability of 'atypical ' neuroleptics to enhance executive functioning as measured with the ToL, WCST, and Stroop test may be due to the short-term character of these studies because oral neuroleptic premedication can influence the receptor binding for at least up to 2 wk (Farde et al., 1992) , and haloperidol is reported to worsen cognitive functioning (Cassens et al., 1990 ; Medalia et al., 1988) . Changes in executive functioning in the treatment with atypical neuroleptics have been shown to occur short term, but studies suggest further improvement with treatment with clozapine for up to 6 months (Harvey and Keefe, 2001) . Studies comparing the potential to enhance cognitive functioning with 'atypical ' neuroleptic agents were mostly short term (i.e. f12 wk ; Keefe et al., 1999) . Therefore, differential changes in cognition, which are reported to have only small effect sizes (Harvey and Keefe, 2001) , may have been affected by aspects of psychopathology or EPS. Long-term studies offer the opportunity to observe differences in the change of executive functioning not only in acute treatment but also in a stabilized population.
Differences between olanzapine and clozapine on executive functioning are reported by Bilder et al. (2002) . In a 14-wk trial patients receiving olanzapine performed significantly better in a set of tests factoranalytically extracted as ' general executive and perceptual organization ' compared to patients receiving either clozapine, haloperidol, or risperidone. Sharma et al. (2003) found no differences in WCST performance between patients treated with olanzanpine and clozapine. Keefe et al. (1999) concluded in a metaanalysis of 15 studies on neurocognitive impairment and atypical neuroleptics that the balance of multiple receptor systems may be most crucial to cognitive functioning and that the cognitive effects of a drug are not predictable exclusively by receptor-binding studies. Possible differences between olanzapine and clozapine may occur because of the more sedating effect of clozapine (Littrell et al., 2000) .
The aims of this study were first, to establish whether changes in executive functioning occur independent of changes in positive symptoms of the psychopathology and independent of side-effects, second, to observe the course of executive functioning not only in short-term, but in long-term treatment, and third, to explore possible differences between the ' atypical ' neuroleptic agents olanzapine and clozapine on executive functioning.
Method

Subjects
In a multi-centre study patients with schizophrenia (DSM-IV) were assigned to 26 wk of randomized, double-blind treatment with olanzapine (n=57) vs. clozapine (n=57) (Naber et al., 2005) . In a subsample of 54 patients [olanzapine (n=30) vs. clozapine (n=24), cf. Table 1 ] executive functioning was assessed.
Patients included in this study had to be considered for clozapine therapy, i.e. they had a documented history that they had either failed to respond to at least one antipsychotic other than clozapine and olanzapine or had experienced intolerable side-effects during these prior antipsychotic treatments. Patients were excluded if they had received prior olanzapine treatment at any time or prior clozapine treatment within the last 3 months before the beginning of the study. Additional criteria included an age ranging from 18 to 65 years and a normalized Brief Psychiatric Rating Scale (BPRS) score of at least 24 as derived from the Positive and Negative Syndrome Scale (PANSS ; Kay et al., 1992) at baseline. Female pregnant or lactating patients were excluded from the study as well as patients with a history of substance abuse or dependence within the past 3 months and patients with serious, unstable somatic illnesses.
Symptom ratings
Patients ' psychopathology (PANSS) and EPS [Simpson-Angus Scale (SAS) ; Simpson and Angus, 1970] were assessed by experienced clinical raters at baseline (T0), after 4 wk (T1) and 26 wk (T2) of treatment.
Neuropsychological tests
Executive functioning was measured using computerized versions of the Stroop test (Stroop, 1935) , the Tower of London test (ToL ; Shallice, 1982) and the Short Wisconsin Card Sorting test (Short WCST ; Nelson, 1976) at T0, T1, and T2.
The computerized Stroop test was divided into three conditions : (1) Selective attention : reaction to bright, but not dark-grey coloured words (40 words) ; (2) Stroop facilitation : word and colour name are identical (40 words ; colours red, blue, yellow and green) and (3) Stroop interference : word and colour name are different (40 words ; colours red, blue, yellow and green). Words were presented for 200 ms with an inter-word interval of 3 s. The subjects had to press a response button (' B ' on the computer keyboard).
The computerized ToL test has been described in detail elsewhere (Schall et al., 1998) . Subjects had to solve 2-7 move problems in the minimum number of moves allowed by moving 3-6 coloured balls on the computer screen with the cursor keys on the keyboard. In addition to the number of correct solutions, planning time (time before the first move is performed) and execution time (time from the first to the final move of each problem) was measured.
The computerized WCST required the subjects to sort cards according to the stimulus dimensions colour, shape and number. The Short WCST (Nelson, 1976) , in contrast to the original version (Grant and Berg, 1948) , accepts the first criterion chosen by the subject as correct for the next cards. After that the change of sorting principle is announced on the computer screen (' The criterion is changed! '). The change of criterion happens five times after six consecutive correct answers.
Study protocol
The study was approved by the local ethics committees and conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the Guidelines on Good Clinical Practice. Subjects gave written informed consent before the washout period. In the week prior to the washout 37 % [olanzapine (n=9), clozapine (n=11)] of the patients received neuroleptic medication (mainly butyrophenones, also phenothiazines, thioxanthenes, risperidone), 54 % [olanzapine (n=13), clozapine (n=16)] received only sedatives or hypnotics (mainly benzodiazepines), and 9 % [olanzapine (n=3), clozapine (n=2)] were medication-free. After a washout of 2-9 days patients were randomly assigned to treatment with either 5-15 mg of olanzapine or 25-200 mg of clozapine. After the third week of treatment the dosage of olanzapine was 5-25 mg, the dosage of clozapine 100-400 mg following clinical criteria.
Randomization schedule was generated by a validated computer program. Patients were assigned the lowest free randomization number available at the study centre. Medication was blinded in capsule form and packaged in blister wallets. To satisfy doubleblind conditions and yet screen for agranulocytosis, blood samples were routinely drawn from all patients.
Concomitant psychotropic medications were not allowed during the study, with the exception of benzodiazepines for agitation (lorazepam up to 8 mg/d, diazepam up to 60 mg/d, oxazepam up to 100 mg/d, temazepam up to 30 mg/d) or chloral hydrate up to 1500 mg/d for insomnia, and biperiden up to 6 mg/d for treatment-emergent EPS. In the olanzapine group at T0 20 patients, at T1 14 patients, and at T2 five patients received sedatives or hypnotics, in the clozapine group at T0 18, at T1 14, and at T2 one patient. Biperiden was administered to four patients of the olanzapine group up to T1 and to one patient of the clozapine group at T0.
Statistical analysis
The data was first analysed using within-subject repeated-measures MANOVAs with Bonferroni correction for multiple testing and post-hoc Scheffé tests (p<0.05) for dependent variables. The PANSS (positive and negative items) and the executive functioning data were then analysed using varimaxrotated principal-component analyses (PCA) to reduce the number of variables when establishing associations between psychopathology, side-effects and executive functioning with Spearman rank correlation. Factor loadings >0.5 were considered in the factor analyses.
Data analysis was divided into two steps using all 54 subjects who completed assessment at T1 for the analysis of the short-term treatment effects and the 31 study completers [olanzapine (n=19), clozapine (n=12)] separately for the analysis of long-term effects.
Results
Overall effects of olanzapine and clozapine on psychopathology, EPS, and executive functioning
Psychopathology and EPS improved significantly over time as well as executive performance in both the olanzapine and clozapine groups (cf . Tables 2 and 3) . Post-hoc Scheffé tests (p<0.05) revealed significant differences in psychopathology between T0, T1, and T2, indicating continuing improvement of positive and negative symptoms for up to 6 months. EPS improved in the short-term course of treatment, but no further improvement occurred at T2 (post-hoc Scheffé test, p<0.05). For a detailed analysis of executive functioning results see below.
Influence of psychopathology and EPS on executive functioning
Factor analyses yielded a stable 4-factor solution for psychopathology (negative, disorganized, two positive factors ; explained variance >75 % respectively) and a stable 4-factor solution for executive functioning (cf. Table 4 ; explained variance >65 % respectively).
Spearman rank correlations showed a weak association between EPS as measured with the SAS and executive functioning at T0 (x0.410, p<0.05) but none at T1 or T2, and no significant correlation of executive functioning with positive psychopathology at all (cf. Table 4 ). Associations of executive functioning with negative symptoms occurred only at T1 (x0.307, p<0.05). A stable correlation was found between disorganization and 'concept formation ' in the short-term course of treatment (T0 : 0.346, p<0.01 ; T1 : 0.332, p<0.05), but not at T2. Only at T2 did disorganization correlate with ' planning/cognitive speed ' (0.458, p<0.05) and ' inhibition/interference ' (x0.461, p<0.05) .
Spearman rank correlations between changes in psychopathology, changes in EPS and changes in executive function only showed trends of positive associations of changes of both ToL planning and execution time with changes in EPS. These effects did not reach statistical significance after correction for multiple testing.
Changes in executive functioning in the course of treatment
Post-hoc Scheffé tests showed a differential pattern of change over time for the neuropsychological tests used : Stroop test performance (correct hits and false alarms) improved significantly at T2 compared to T0 and T1 as did ToL planning time, whereas WCST (correct hits, perseverative errors, and total errors) and ToL execution time improved significantly at T1 with no further improvement at T2 (post-hoc Scheffé test, p<0.05 ; cf. Table 3 ).
Differences between olanzapine and clozapine on executive functioning and psychopathology
In general olanzapine and clozapine both improved psychopathology and executive performance in a comparable manner. Differences in psychopathology improvement occurred in the PANSS negative score where the clozapine group changed to a greater extent although it showed a slightly worse psychopathology at T0 [T0-T1 : F(1, 52)=4.20, p<0.05 ; T0-T1-T2 : F(1, 23)=4.95, p<0.05]. The only difference in executive functioning occurred in Stroop reaction time, where a medication r time interaction indicated an improvement in the olanzapine group and a deterioration in the clozapine group (p<0.05, Figure 1 ). Although this effect was significant for the difference between the two agents in general, it was most prominent in the selective attention condition and considerably less marked in Stroop interference and Stroop facilitation. 
Discussion
Influence of psychopathology and EPS on executive functioning
In this study -as expected -executive functioning as well as psychopathology and EPS improved over time. The improvement in EPS was statistically significant at T1, but no further improvement occured at T2. This may be due to the fact that in the week before washout only 37 % of the study population received neuroleptic medication. Therefore the EPS were slight at T0, only five patients received biperiden up to T1 where these side-effects were already below clinical significance. None of the patients received biperiden later than T1.
With the exception of a non-significant trend for ToL planning and execution time, improvement of executive functioning did not correlate with the improvement of EPS. Considering that most neuropsychological functions are influenced even by mild EPS (Cassens et al., 1990) , previous studies have not been able to distinguish between secondary (caused by lower EPS rates) and primary (specific effect on cognition) effects of antipsychotic medication (Weiss PANSS, Positive and Negative Syndrome Scale ; SAS, Simpson-Angus Scale ; WCST, Wisconsin Card Sorting test ; ToL, Tower of London test. * p<0.001, ** p<0.01, *** p<0.05 ; p values shown are MANOVA improvements over time within both groups (olanzapine and clozapine), the results at T2 indicating a T0-T1-T2 comparison. Significant differences between both groups (olanzapine and clozapine) are given in bold italics (PANSS negative score and Stroop reaction times, p<0.05 each). Post-hoc Scheffé tests (p<0.5) : a=significant differences between T0 and T1 and T2 ; b=significant difference between T0 and T1, T2 (short-term improvement) ; c=significant difference between T0, T1 and T2 (long-term improvement).
et al., 2002). Our results indicate a true drug effect of olanzapine and clozapine on executive functioning that is unrelated to a lower rate of EPS. Similar to the problem of motor side-effects and executive functioning, neurocognitive deficits may be seen as a secondary effect of positive symptomatology. Studies differentiating solely between positive and negative psychopathology frequently show an association between frontal, executive tasks and positive symptoms (Zakzanis, 1998) , whereas studies using the three-dimensional approach (the division into positive, negative and disorganized symptoms) proposed by Bilder et al. (1985) and Liddle (1987) usually fail to show an association between positive symptoms and neurocognitive impairments. Moritz et al. (2001) suggest a class of (negative) symptoms caused by 'internal immigration ' of the patients as a result of positive symptomatology. Cognitive deficits caused by this kind of rather secondary negative symptoms cannot be distinguished from 'real' negative symptoms and, therefore, remain to be clarified (Kirkpatrick et al., 2001 ). In our study improvement of executive functioning did not correlate with improvement of positive symptoms.
In summary, given the absence of correlation between improvement of executive functioning and improvement of EPS and positive symptoms, we therefore consider the improvement of executive functioning to be a primary effect of the treatment with olanzapine and clozapine not mediated by changes in positive symptoms and adverse events (EPS).
Changes in executive functioning in the course of treatment
Negative symptoms and disorganization on the other hand did correlate with executive test factors. This was most prominent during the point in time when the underlying neuropsychological tests changed significantly as analysed with post-hoc Scheffé tests (for WCST T1, for Stroop and ToL T2) . These results support the findings of Himelhoch et al. (1996) postulating a relationship of WCST perseverative errors and disorganization and of Ngan and Liddle (2000) who claim a general association of negative symptoms with selective processes and of disorganization with disturbed initiation and slower processing of stimuli.
The improvement in executive functioning showed short-term as well as long-term effects. Especially ToL and WCST performance benefited from the longterm treatment (T2). Treatment with clozapine has been shown to continue to improve positive and negative symptoms for at least 6 months, whereas the time-course of cognitive enhancement with ' atypical ' antipsychotics is presently unknown (Harvey and Keefe, 2001) . Therefore, future studies on cognitive improvement by neuroleptic treatment should last at least up to 6 months, and perhaps even longer. These findings also pose questions about definition of non-response to neuroleptic treatment in general. Many definitions of non-response (not only regarding cognitive dysfunction but overall psychopathology ; e.g. Brenner et al., 1990 ; Barnes and McEvedy, 1996) , including the most widely used definition by Kane et al. (1988) , define non-response as persistence of symptoms despite a 6-wk period of neuroleptic treatment using a sufficient dosage. These concepts are reflected in current guidelines for the treatment of patients with schizophrenia, such as the The Expert Consensus Guideline Series (McEvoy et al., 1999) or the guideline of the German Psychiatric Association (DGPPN) (Deutsche Gesellschaft fü r Psychiatrie, Psychotherapie und Nervenheilkunde, 1998). The latter, for example, recommends in the case of nonresponse a change of the antipsychotic agent in use already after 4 wk of treatment with neuroleptics other than clozapine or after 4-6 wk of clozapine treatment. Thus, our findings supporting evidence of continued improvement of disturbed function in patients with schizophrenia after more than 6 wk of medication (Harvey and Keefe, 2001 ) could also prompt us to re-examine definitions of non-response to antipsychotic medication -at least regarding cognitive dysfunction but maybe even regarding overall psychopathology -as well as corresponding treatment guidelines.
Differences between olanzapine and clozapine on executive functioning and psychopathology Two recent studies provided inconsistent results. While Bilder et al. (2002) found generally improved executive performance and also improved perceptual organization on a set of tasks when comparing patients on olanzapine vs. clozapine, Sharma et al. (2003) did not find any differential drug effect when assessing executive function with the WCST. In our study however, a differential drug effect was only observed for negative symptoms and Stroop reaction time.
The improvement of negative symptoms was significantly better in the course of treatment with clozapine than with olanzapine. This may be seen as an indicator of the antidepressant effect of an a 2 receptor binding agent proposed by Leysen (1999) . Negative symptoms like blunted affect, emotional and social withdrawal are also components of a depressive syndrome. However, the clinical relevance of the differences in the improvement of negative symptoms in the present study (olanzapine 17.2 vs. clozapine 15.1 at T2) is at best marginal.
Executive functioning was enhanced by both neuroleptics in a comparable manner with the exception of Stroop reaction times, where patients treated with olanzapine improved whereas patients treated with clozapine deteriorated. Differences in motor performance as measured by Stroop reaction times may be due to the sedating effects of clozapine as reported in the literature (Littrell et al., 2000) . The effect was most prominent in the selective attention condition and much less so in the two 'real' Stroop conditions. The selective attention condition did not involve actually reading the words given on the computer screen, but only reacting to words given in one colour and not to the words given in another colour. It therefore resembles the 'Card B' of the classical Stroop test. Thus, we cannot conclude an actual difference between olanzapine and clozapine concerning the Stroop interference and facilitation conditions and their underlying processes of selective attention and automatic spreading.
As clozapine is still considered the 'gold standard' of neuroleptic treatment for cognitive dysfunction, with respect to executive functioning our data implies olanzapine is a very appropriate alternative without the legal restrictions of clozapine treatment and apparently less sedating effects (Tollefson et al., 2001) .
The selection of the participants in previous studies on cognitive functioning in schizophrenia has been unsystematic. This still presents a problem in our study as patients were not specifically selected on the basis of their level of cognitive dysfunction. Whereas inclusion criteria for studies on antipsychotic medication normally include a certain level of psychopathology as measured by rating scales such as PANSS or BPRS, no such criteria are yet defined for the cognitive symptoms of the disease. No consensus has been found yet regarding the relative importance of specific aspects of cognitive functioning and which tests should be used to measure them (Harvey and Keefe, 2001) .
The selected population in this study is certainly not representative for schizophrenia due to the eligibility criteria for clozapine in Germany. To be considered for clozapine treatment a person must have either a history of non-response to two different neuroleptics or experienced severe side-effects while taking such medication. Although all patients in this study met these criteria and, therefore, might be considered a rather difficult to treat population, they all gained significant benefit from taking either olanzapine or clozapine, not only regarding psychopathology and EPS, but also executive functioning.
